TOPLINE:
Zimlovisertib plus tofacitinib showed greater efficacy than tofacitinib alone in reducing Disease Activity Score in 28 joints using C-reactive protein (DAS28-CRP) in patients with rheumatoid arthritis (RA), with a significant reduction observed at week 12.
METHODOLOGY:
- This randomized, phase 2 study, conducted across 77 centers in 10 countries, aimed to evaluate the efficacy, safety, and pharmacokinetic profiles of zimlovisertib in combination with tofacitinib or ritlecitinib compared with tofacitinib alone in 460 patients (age, 18-70 years) with moderate to severe RA.
- Participants were randomly assigned to five groups: 400 mg zimlovisertib modified release (MR) + 11 mg tofacitinib MR (n = 103), 400 mg zimlovisertib MR + 100 mg ritlecitinib (n = 101), 400 mg…